CARL ZEISS MEDITEC ADR 1 (AFXA) — Working Capital to Net Assets Ratio
CARL ZEISS MEDITEC ADR 1 (AFXA) has a Working Capital to Net Assets ratio of 34.2% as of September 2025. Working capital of €728.13 Million (current assets of €1.27 Billion minus current liabilities of €543.81 Million) is measured against net assets of €2.13 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See CARL ZEISS MEDITEC ADR 1 balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
CARL ZEISS MEDITEC ADR 1 Working Capital to Net Assets (2022–2025)
This chart shows how CARL ZEISS MEDITEC ADR 1's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of September 2025, the ratio stands at 34.2%, reflecting working capital of €728.13 Million against net assets of €2.13 Billion EUR. Check CARL ZEISS MEDITEC ADR 1 (AFXA) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for CARL ZEISS MEDITEC ADR 1 (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for CARL ZEISS MEDITEC ADR 1 from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see AFXA stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 34.2% | €728.13 Million | €2.13 Billion | €1.27 Billion | €543.81 Million | ▲ +3.1 pp |
| 2024 | 31.1% | €639.09 Million | €2.06 Billion | €1.21 Billion | €568.84 Million | ▼ -31.1 pp |
| 2023 | 62.1% | €1.35 Billion | €2.17 Billion | €1.91 Billion | €561.65 Million | ▲ +0.4 pp |
| 2022 | 61.7% | €1.25 Billion | €2.03 Billion | €1.79 Billion | €539.32 Million | — |